ICON

Silver Sponsor

Information


ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 84 locations in 38 countries and has approximately 12,300 employees. Further information is available at www.iconplc.com.

Contact details

http://www.iconplc.com/

Sessions

Update on EMA & EU payers new initiative: Dialogue to explore synergies, foster mutual understanding & cooperation to improve timely & affordable access to new medicinal products

Tuesday, November 3, 2020 8:30 AM to 9:30 AM
Plenary Keynote

Panel: Are HTAs ready to receive info from wearables?

Tuesday, November 3, 2020 1:35 PM to 2:05 PM
Clinical Development

Innovative payment models for cell & gene therapies

Wednesday, November 4, 2020 3:40 PM to 4:40 PM
Plenary Keynote

How European countries are-shaping access to ATMPs: RWE infrastructure, innovative payments and funding

Thursday, November 5, 2020 8:40 AM to 9:10 AM
Cell & Gene Therapy

Documents & Links

Brochure Rare DiseaseOvercoming the Challenges of Rare Disease Drug Development
Case Study Patient Centricity in Orphan Drug Development Patient Reported Outcomes measures in the development of drugs for patients with rare diseases
Case Study Progressive Supranuclear PalsyPatient Support Services Boost Recruitment in Study for Progressive Supranuclear Palsy. Recruitment Completed Over Three Weeks Early
Case Study Rare Disease HuntingtonComplex, Early-Phase Study in Huntington’s Disease Careful Planning and Close Coordination Across Vendors Speeds Start-Up and Recruitment
Case Study Rare Disease PKUPKU-specific HRQol Questionnaire Development & Validation - Measuring the disease impact on patients and their caregivers
Case Study Triple Negative Breast CancerVirtual Development Model - Accelerating the development of rare disease therapies
Case Study HCVM VaccineHuman Cytomegalovirus Vaccine Development - Uncovering patient insights to accelerate clinical research
Case Study CIPD Patient SurveyChronic inflammatory demyelinating polyneuropathy (CIPD) - Uncovering insights to understand the patient journey
Case Study Achondroplasia InsightsAchondroplasia - Uncovering patient insights to drive study enrolment
Case Study Rare Disease MereoVirtual Development Model - Accelerating the development of rare disease therapies

Log in